NCT00041197View on ClinicalTrials.gov

Imatinib Mesylate in Treating Patients With Primary Gastrointestinal Stromal Tumor That Has Been Completely Removed By Surgery

PHASE3CompletedINTERVENTIONAL

Enrollment

732

Participants

Timeline

Start Date

June 30, 2002

Primary Completion Date

April 30, 2007

Conditions

Gastrointestinal Stromal Tumor

Interventions

DRUG

imatinib mesylate

Given orally (PO)

OTHER

placebo

Given PO

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

27705

American College of Surgeons Oncology Group, Durham

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH

NCT00041197 - Imatinib Mesylate in Treating Patients With Primary Gastrointestinal Stromal Tumor That Has Been Completely Removed By Surgery | Biotech Hunter | Biotech Hunter